(Q40949103)

25 September 2017

title

VX-509 (Decernotinib), an Oral Selective JAK-3 Inhibitor, in Combination With Methotrexate in Patients With Rheumatoid Arthritis (English)

1 reference

25 September 2017

1 reference

Ronald van Vollenhoven

2

object named as

Ronald F van Vollenhoven

0 references

author name string

Mark C Genovese

1

1 reference

25 September 2017

César Pacheco-Tena

3

1 reference

25 September 2017

Yanqiong Zhang

4

1 reference

25 September 2017

Nils Kinnman

5

1 reference

25 September 2017

publication date

16 October 2015

1 reference

25 September 2017

published in

Arthritis & Rheumatology

1 reference

25 September 2017

volume

68

1 reference

25 September 2017

issue

1

1 reference

25 September 2017

page(s)

46-55

1 reference

Kinase inhibitors: a new class of antirheumatic drugs

25 September 2017

cites work

1 reference

Janus kinases in immune cell signaling

21 January 2018

1 reference

Expression of Jak3, STAT1, STAT4, and STAT6 in inflammatory arthritis: unique Jak3 and STAT4 expression in dendritic cells in seropositive rheumatoid arthritis

21 January 2018

1 reference

Jaks and STATs: biological implications

21 January 2018

1 reference

A randomized, double-blind, placebo-controlled, twelve-week, dose-ranging study of decernotinib, an oral selective JAK-3 inhibitor, as monotherapy in patients with active rheumatoid arthritis

21 January 2018

1 reference

The american rheumatism association 1987 revised criteria for the classification of rheumatoid arthritis

21 January 2018

1 reference

American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis

21 January 2018

1 reference

Joint damage in rheumatoid arthritis progresses in remission according to the Disease Activity Score in 28 joints and is driven by residual swollen joints

21 January 2018

1 reference

Measurement of patient outcome in arthritis

21 January 2018

1 reference

Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: findings of a phase IIIb, multinational, prospective, randomized study

21 January 2018

1 reference

Kinase inhibitors: the next generation of therapies in the treatment of rheumatoid arthritis

21 January 2018

1 reference

Phase 2 study of the JAK kinase inhibitor ruxolitinib in patients with refractory leukemias, including postmyeloproliferative neoplasm acute myeloid leukemia

21 January 2018

1 reference

Herpes zoster and tofacitinib therapy in patients with rheumatoid arthritis

21 January 2018

1 reference

Interaction of IL-2R beta and gamma c chains with Jak1 and Jak3: implications for XSCID and XCID

21 January 2018

1 reference

Functional activation of Jak1 and Jak3 by selective association with IL-2 receptor subunits

21 January 2018

1 reference

JAK3 specific kinase inhibitors: when specificity is not enough.

21 January 2018

1 reference

Signaling through the hematopoietic cytokine receptors.

21 January 2018

1 reference

Can unequal be more fair? Ethics, subject allocation, and randomised clinical trials

21 January 2018

1 reference

Can unequal be more fair? A response to Andrew Avins

21 January 2018

1 reference

The questionable use of unequal allocation in confirmatory trials

21 January 2018

1 reference

Differences in synovial tissue infiltrates between anti–cyclic citrullinated peptide–positive rheumatoid arthritis and anti–cyclic citrullinated peptide–negative rheumatoid arthritis

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1002/ART.39473

1 reference

25 September 2017

1 reference